Literature DB >> 19740351

Identification and characterization of the interferon-beta-mediated p53 signal pathway in human peripheral blood mononuclear cells.

Fanglin Zhang1, Subramaniam Sriram.   

Abstract

The relationship between the p53 signal pathway and the response of human peripheral blood mononuclear cells (PBMC) to interferon (IFN)-beta has hitherto not been examined. Using an oligonucleotide microarray, we found differential expression of at least 70 genes involved in the p53 signal pathway, including p53, which regulate cell proliferation and cell death following stimulation with IFN-beta. We verified our observations on a limited set of p53-regulated genes at the transcriptional and translational levels. We also examined the consequences of the activation of the p53 signal pathway by IFN-beta in PBMC. When cultured in the presence of T-cell mitogens, IFN-beta restricted the entry of lymphocytes from the G0/G1 phase to the S phase and reduced the number of cells in the G2 phase. The addition of IFN-beta alone did not increase apoptosis. However, in the presence of actinomycin D, a DNA-damaging agent, addition of IFN-beta enhanced the susceptibility of PBMC to apoptosis. These observations suggest that, in spite of the activation of a number of mutually overlapping pathways mediating cell death, cell cycle arrest was the most evident consequence of IFN-beta signalling in PBMC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740351      PMCID: PMC2753925          DOI: 10.1111/j.1365-2567.2009.03104.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites.

Authors:  Hua Qian; Ting Wang; Louie Naumovski; Charles D Lopez; Rainer K Brachmann
Journal:  Oncogene       Date:  2002-11-07       Impact factor: 9.867

Review 3.  Stats: transcriptional control and biological impact.

Authors:  David E Levy; J E Darnell
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

Review 4.  Therapy of acute hepatitis C.

Authors:  Alfredo Alberti; Silvia Boccato; Alessandro Vario; Luisa Benvegnù
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

5.  Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

Authors:  K P Wandinger; C S Stürzebecher; B Bielekova; G Detore; A Rosenwald; L M Staudt; H F McFarland; R Martin
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

6.  Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis.

Authors:  M K Sharief; Y K Semra; O A Seidi; Y Zoukos
Journal:  J Neuroimmunol       Date:  2001-11-01       Impact factor: 3.478

7.  Upregulation of the inhibitor of apoptosis proteins in activated T lymphocytes from patients with multiple sclerosis.

Authors:  M K Sharief; Y K Semra
Journal:  J Neuroimmunol       Date:  2001-10-01       Impact factor: 3.478

8.  Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells.

Authors:  J Kleeff; M Kornmann; H Sawhney; M Korc
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

9.  Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.

Authors:  Bianca Weinstock-Guttman; Kavitha Bhasi; Darlene Badgett; Miriam Tamaño-Blanco; Miranda Minhas; Joan Feichter; Kara Patrick; Frederick Munschauer; Rohit Bakshi; Murali Ramanathan
Journal:  J Neuroimmunol       Date:  2008-10-23       Impact factor: 3.478

10.  TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis.

Authors:  Klaus-Peter Wandinger; Jan D Lünemann; Oliver Wengert; Judith Bellmann-Strobl; Orhan Aktas; Alexandra Weber; Eva Grundström; Stefan Ehrlich; Klaus-D Wernecke; Hans-Dieter Volk; Frauke Zipp
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

View more
  9 in total

1.  Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.

Authors:  Joshua F Heiber; Glen N Barber
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

2.  MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response.

Authors:  Kenneth W Witwer; Jeanne M Sisk; Lucio Gama; Janice E Clements
Journal:  J Immunol       Date:  2010-02-03       Impact factor: 5.422

Review 3.  p53 Isoforms as Cancer Biomarkers and Therapeutic Targets.

Authors:  Liuqun Zhao; Suparna Sanyal
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

4.  Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis.

Authors:  Fanglin Zhang; Yaping Shi; Lily Wang; Subramaniam Sriram
Journal:  PLoS One       Date:  2011-02-08       Impact factor: 3.240

5.  C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event.

Authors:  Zachary J Messenger; Jonathan R Hall; Dereje D Jima; John S House; Hann W Tam; Debra A Tokarz; Robert C Smart
Journal:  Cell Death Dis       Date:  2018-10-15       Impact factor: 8.469

6.  Optimal regulation of tumour-associated neutrophils in cancer progression.

Authors:  Aurelio A de Los Reyes; Yangjin Kim
Journal:  R Soc Open Sci       Date:  2022-02-02       Impact factor: 2.963

7.  Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta.

Authors:  Marta F Bustamante; Ramil N Nurtdinov; Jordi Río; Xavier Montalban; Manuel Comabella
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

8.  Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.

Authors:  Shalom Madar; Einav Harel; Ido Goldstein; Yan Stein; Ira Kogan-Sakin; Iris Kamer; Hilla Solomon; Elya Dekel; Perry Tal; Naomi Goldfinger; Gilgi Friedlander; Varda Rotter
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

9.  Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model.

Authors:  Yangjin Kim; Donggu Lee; Junho Lee; Seongwon Lee; Sean Lawler
Journal:  PLoS One       Date:  2019-01-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.